• To determine the proportion of patients who are alive and without disease progression 1 year after initiating Rituxan plus 1018 ISS therapy. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  

• To assess the overall response rate following treatment [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  
• to determine duration of response and time to progression [ Time Frame: TBD ] [ Designated as safety issue: No ]
  
• to further define the safety profile of 1018 ISS [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  
• to explore the biologic activity of 1018 ISS. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  

Drug: Rituxan
Given intravenously once weekly for four weeks.
Drug: 1018 ISS
Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.

• Patients will receive four weekly infusions of Rituxan which is standard treatment for B-cell non-Hodgkin's lymphoma. Approximately 30 to 60 minutes after the second, third and fourth infusions of Rituxan, the patient will receive up to 3 injections of 1018 ISS under the skin. The number of injections will depend upon the patients weight. One week after the last Rituxan infusion the patient will receive a fourth and final injection of 1018 ISS.
• After completion of the 5-week treatment period, a physical examination and blood work will be performed. The patient will also be examined to see if the tumor has gotten smaller, bigger, or stayed the same size and in the same places by either CT scan or MRI. A bone marrow aspiration and biopsy will be done to examine any changes in bone marrow cells.
• The following tests will be performed to determine whether or not a patient is eligible to participate in this clinical study: Bone marrow aspiration and biopsy; lymph node biopsy; skin biopsy; standard x-ray tests (x-rays, CT scans, MRI, ultrasounds, and/or radioactive drug scans); and blood work.
• While receiving treatment patients will have the following procedures done; Physical examination once a week for 4 weeks, blood testing for any changes in the blood, blood chemistry and other blood components. Patients will also be requested to keep a diary between each study visit to record any health changes or any over-the-counter medication or herbal preparation they may have taken.

Inclusion Criteria:

• 18 years of age or older
• Pathological evidence of CD20+, B-cell follicular non-Hodgkin's lymphoma
• Received at least one previous chemotherapy regimen for lymphoma
• Hemoglobin > 8.5 g/dl
• WBC > 2,000/mm3
• ANC > 1,000/mm3
• Platelet count > 75,000/mm3
• ECOG performance status of less than or equal to 2
• Life expectancy of greater than 4 months
• Women and men of childbearing potential must be willing to use highly effective methods of birth control for duration of time on the study

Exclusion Criteria:

• Pregnant of lactating women
• Treatment with chemotherapy, including systemic steroids, or radiation therapy within 30 days
• Current use of systemic or inhaled steroids
• Treatment with radioimmunotherapy, autologous stem cell transplantation, or fludarabine within 6 months
• Disease progression within 6 months of any previous rituximab therapy
• History of allogenic transplantation, including nonmyeloablative transplantation
• Unstable angina, symptomatic cardiac arrhythmia or clinical heart failure
• Severe pulmonary disease, symptomatic pleural effusions, or clinically significant pulmonary symptoms
• Active infection requiring systemic antibiotic, antiviral, or antifungal therapy
• Clinically apparent CNS lymphoma
• Major surgery within 2 weeks
• Known human anti-murine antibody (HAMA) or human anti-chimeric antibody (HACA) response
• Known Hepatitis B surface antigen positive
• History of autoimmune disorder
• Current therapeutic use of anticoagulants
• History of coagulopathy
• Known allergy to any of the components of 1018 ISS or Rituxan
• Participation in another investigational trial within 30 days
• Any clinically significant abnormality in screening blood chemistry, hematology, or urinalysis